Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
DBV Technologies S.A. develops treatment options for food allergies and other immunologic conditions as a late-stage biopharmaceutical company. Company updates center on the proprietary VIASKIN® patch technology, epicutaneous immunotherapy, and the VIASKIN Peanut program for peanut-allergic toddlers and children.
Recurring developments include clinical data from the Phase 3 VITESSE study, annual and quarterly financial results, financing and warrant-related capital actions, leadership and governance changes, share and voting-rights disclosures under French market rules, and market information tied to DBVT American Depositary Shares.
DBV Technologies, a clinical-stage biopharmaceutical company, will report its first half 2021 financial results and business updates on August 2, 2021. A conference call and live audio webcast will take place at 5:00 p.m. ET. Viaskin™, the company's investigational platform for immunotherapy, aims to transform the care of food allergic patients, with ongoing trials for Viaskin Peanut. The presentation will be available on their website, along with a replay post-event.
As of June 30, 2021, the total number of shares for the company was 55,011,687. This included 54,933,812 voting rights after accounting for shares without voting rights. This information is disclosed in compliance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers and is crucial for investors monitoring voting power and company governance. The data is available on the NYSE Euronext Paris market under the ISIN Code: FR 0010417345.
As of May 31, 2021, the company reported a total of 55,011,687 shares outstanding. The total gross voting rights are also at 55,011,687, while the net voting rights stand at 54,943,413. This announcement complies with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that CEO Daniel Tassé will participate in two upcoming virtual investor conferences in June 2021. The first is at the Goldman Sachs Global Healthcare Conference on June 8, 2021, at 8:50am ET, followed by the JMP Life Sciences Conference on June 16, 2021, at 10:00am ET. A live webcast of these events will be available on the company's website, where replays will also be accessible later. DBV is focused on developing Viaskin™, a technology aimed at immunotherapy for food allergies.
DBV Technologies, a clinical-stage biopharmaceutical company, held its Ordinary and Extraordinary General Meeting on May 19, 2021, where shareholders approved all proposed resolutions. Notably, Dr. Adora Ndu and Dr. Ravi Madduri Rao were appointed as independent board members, while Dr. Torbjorn Bjerke retired. The board now consists of ten directors. Dr. Ndu and Dr. Rao bring extensive experience in drug development and regulatory affairs, aiming to support the strategic objectives of DBV, particularly in the advancement of Viaskin Peanut.
As of April 30, 2021, the company reported a total of 54,936,687 shares outstanding. The total number of voting rights amounted to 54,936,687 gross and 54,887,687 net after excluding non-voting shares. This information is compliant with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers. The data reflects important metrics regarding shareholder influence and governance.
DBV Technologies has filed its first Form 10-Q for Q1 2021 with the U.S. SEC. This document is available on both the company's website and the SEC’s website. DBV Technologies is focused on developing Viaskin™, a non-invasive immunotherapy platform aimed at treating food allergies, including ongoing trials for Viaskin Peanut. The company operates globally with headquarters in France and North American operations in New Jersey, and its stock is traded on Euronext Paris and Nasdaq (ticker: DBVT).
DBV Technologies reported its Q1 2021 financial results, showing a cash balance of $152.5 million as of March 31, down from $196.4 million at year-end 2020. The net loss narrowed to $(29.4 million), or $(0.54) per share, compared to $(40.9 million) and $(0.79) per share in Q1 2020. Operating income fell 37.7% to $2.9 million, primarily due to reduced research tax credits. Operating expenses decreased 29.2% to $32.6 million, attributed to workforce reductions. DBV expects current cash reserves to fund operations until mid-2022.
DBV Technologies (Euronext: DBV, Nasdaq: DBVT), a clinical-stage biopharmaceutical firm, announced participation in two virtual investor conferences in May 2021. Dr. Pharis Mohideen and CFO Sebastien Robitaille will represent the company at the Kempen Life Sciences Conference on May 5, while CEO Daniel Tassé and Robitaille will attend the Societe Generale Nice Conference on May 27. DBV is focused on developing Viaskin™, a novel technology platform for immunotherapy aimed at treating food allergies through epicutaneous delivery.
DBVT released monthly data regarding the total number of shares and voting rights as of April 14, 2021. The total number of shares stands at 54,936,687, while the total gross of voting rights is also 54,936,687. The total net of voting rights, defined as the total voting rights minus shares without voting rights, is 54,895,437. This disclosure fulfills the requirements under Article 223-16 of the General Regulations of the Autorité des Marchés Financiers, emphasizing transparency in shareholder voting power.